| Ruthenium (II)‐Dithiocarbazates as Anticancer Agents: Synthesis, Solution Behavior, and Mitochondria‐Targeted Apoptotic Cell Death G Sahu, SA Patra, S Lima, S Das, H Görls, W Plass, R Dinda Chemistry–A European Journal 29 (18), e202202694, 2023 | 29 | 2023 |
| Recent Advances in Mitochondria‐Localized Luminescent Ruthenium (II) Metallodrugs as Anticancer Agents SA Patra, G Sahu, S Das, R Dinda ChemMedChem 18 (22), e202300397, 2023 | 7 | 2023 |
| Insights into the Theranostic Activity of Nonoxido VIV: Lysosome-Targeted Anticancer Metallodrugs PD Pattanayak, A Banerjee, G Sahu, S Das, S Lima, O Akintola, ... Inorganic Chemistry 63 (41), 19418-19438, 2024 | 2 | 2024 |
| RuIII–Morpholine-Derived Thiosemicarbazone-Based Metallodrugs: Lysosome-Targeted Anticancer Agents M Mohanty, S Das, PD Pattanayak, S Lima, W Kaminsky, R Dinda ACS Applied Bio Materials, 2025 | | 2025 |